Vor Biopharma (NASDAQ:VOR) Now Covered by Analysts at William Blair

Equities research analysts at William Blair began coverage on shares of Vor Biopharma (NASDAQ:VOR) in a research report issued on Wednesday, Briefing.com reports. The firm set an “outperform” rating on the stock.

A number of other research firms have also recently commented on VOR. Citigroup upgraded Vor Biopharma to a “strong-buy” rating in a report on Thursday, October 15th. Wall Street Zen raised Vor Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Wedbush raised their target price on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings upgraded Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 14th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Vor Biopharma presently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Vor Biopharma Stock Up 5.5%

Shares of VOR stock opened at $19.03 on Wednesday. The firm’s 50-day moving average is $21.38 and its two-hundred day moving average is $18.41. Vor Biopharma has a 12 month low of $6.50 and a 12 month high of $30.38.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). As a group, equities analysts predict that Vor Biopharma will post -2.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors have recently modified their holdings of the company. Cannon Global Investment Management LLC acquired a new position in Vor Biopharma during the 1st quarter worth about $209,000. Sei Investments Co. acquired a new position in Vor Biopharma in the 1st quarter valued at about $245,000. Independent Financial Group LLC acquired a new position in Vor Biopharma in the 1st quarter valued at about $249,000. Wellington Management Group LLP acquired a new position in Vor Biopharma in the 2nd quarter valued at about $499,000. Finally, Irenic Capital Management LP purchased a new stake in Vor Biopharma during the first quarter worth about $583,000. 97.29% of the stock is owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company’s approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor’s technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets.